サマリー

特発性肺線維症治療は、肺の組織が硬くなってしまう肺の病気に対する治療作業です。

市場分析と洞察。特発性肺線維症治療薬の世界市場
特発性肺線維症治療薬の世界市場規模は、2020年の1895.9百万米ドルから2027年には3180百万米ドルに達すると予測され、2021年から2027年の間、7.2%のCAGRで推移すると予想されます。
本レポートは、業界標準の正確な分析と高いデータの整合性により、特発性肺線維症治療薬の世界市場で得られる主要な機会を明らかにし、プレイヤーが市場での確固たる地位を獲得するのに役立つ見事な試みを行っています。本レポートの購入者は、特発性肺線維症治療薬の世界市場全体の規模（売上高）など、検証済みの信頼できる市場予測にアクセスすることができます。
本レポートは、特発性肺線維症治療薬の世界市場において、競合他社に対して優位に立ち、永続的な成功を収めるための効果的なツールであることを証明しています。本レポートに掲載されているすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証、再検証されています。本レポートを執筆したアナリストは、世界の特発性肺線維症治療市場を詳細に調査するために、独自の業界最高水準の調査・分析手法を用いています。

世界の特発性肺線維症治療のスコープと市場規模
特発性肺線維症治療薬市場は、企業別、地域（国）別、タイプ別、用途別に分類されています。世界の特発性肺線維症治療市場に参加するプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年の期間で、タイプ別とアプリケーション別の収益と予測に焦点を当てています。

タイプ別セグメント
薬剤クラス
酸素療法
肺移植
その他

用途別セグメント
病院
クリニック

地域別
北アメリカ
U.S.
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
北欧
その他のヨーロッパ諸国
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア諸国
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他の中東・アフリカ地域

会社別
バイオジェン
ベーリンガーインゲルハイムGMBH
ブリストル・マイヤーズ スクイブ社
シプラ社
ホフマン・ラ・ロシュ社
ファイブロジェン社
Galapagos NV
メディシノバ・インク
メルク・アンド・カンパニー・インク
ノバルティス社
Prometic Life Sciences Inc.

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Class
1.2.3 Oxygen Therapy
1.2.4 Lung Transplant
1.2.5 Others
1.3 Market by Application
1.3.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Perspective (2016-2027)
2.2 Idiopathic Pulmonary Fibrosis Treatment Growth Trends by Regions
2.2.1 Idiopathic Pulmonary Fibrosis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Idiopathic Pulmonary Fibrosis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Idiopathic Pulmonary Fibrosis Treatment Industry Dynamic
2.3.1 Idiopathic Pulmonary Fibrosis Treatment Market Trends
2.3.2 Idiopathic Pulmonary Fibrosis Treatment Market Drivers
2.3.3 Idiopathic Pulmonary Fibrosis Treatment Market Challenges
2.3.4 Idiopathic Pulmonary Fibrosis Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Pulmonary Fibrosis Treatment Players by Revenue
3.1.1 Global Top Idiopathic Pulmonary Fibrosis Treatment Players by Revenue (2016-2021)
3.1.2 Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Pulmonary Fibrosis Treatment Revenue
3.4 Global Idiopathic Pulmonary Fibrosis Treatment Market Concentration Ratio
3.4.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Pulmonary Fibrosis Treatment Revenue in 2020
3.5 Idiopathic Pulmonary Fibrosis Treatment Key Players Head office and Area Served
3.6 Key Players Idiopathic Pulmonary Fibrosis Treatment Product Solution and Service
3.7 Date of Enter into Idiopathic Pulmonary Fibrosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Idiopathic Pulmonary Fibrosis Treatment Breakdown Data by Type
4.1 Global Idiopathic Pulmonary Fibrosis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Type (2022-2027)

5 Idiopathic Pulmonary Fibrosis Treatment Breakdown Data by Application
5.1 Global Idiopathic Pulmonary Fibrosis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
6.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
6.2.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
6.2.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
6.2.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
6.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
6.3.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
6.3.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
6.3.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
6.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
6.4.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
6.4.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
7.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
7.2.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
7.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
7.3.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
7.4 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
7.4.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
8.2.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
8.3.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region
8.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
9.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
9.2.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
9.3 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
9.3.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
9.4 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
9.4.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
10.2.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
10.3.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
10.4.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Idiopathic Pulmonary Fibrosis Treatment Introduction
11.1.4 Biogen Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Boehringer Ingelheim GMBH
11.2.1 Boehringer Ingelheim GMBH Company Details
11.2.2 Boehringer Ingelheim GMBH Business Overview
11.2.3 Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Introduction
11.2.4 Boehringer Ingelheim GMBH Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.2.5 Boehringer Ingelheim GMBH Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Details
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Cipla
11.4.1 Cipla Company Details
11.4.2 Cipla Business Overview
11.4.3 Cipla Idiopathic Pulmonary Fibrosis Treatment Introduction
11.4.4 Cipla Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.4.5 Cipla Recent Development
11.5 Hoffmann-La Roche AG
11.5.1 Hoffmann-La Roche AG Company Details
11.5.2 Hoffmann-La Roche AG Business Overview
11.5.3 Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Introduction
11.5.4 Hoffmann-La Roche AG Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.5.5 Hoffmann-La Roche AG Recent Development
11.6 Fibrogen, Inc.
11.6.1 Fibrogen, Inc. Company Details
11.6.2 Fibrogen, Inc. Business Overview
11.6.3 Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.6.4 Fibrogen, Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.6.5 Fibrogen, Inc. Recent Development
11.7 Galapagos NV
11.7.1 Galapagos NV Company Details
11.7.2 Galapagos NV Business Overview
11.7.3 Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Introduction
11.7.4 Galapagos NV Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.7.5 Galapagos NV Recent Development
11.8 Medicinova, Inc.
11.8.1 Medicinova, Inc. Company Details
11.8.2 Medicinova, Inc. Business Overview
11.8.3 Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.8.4 Medicinova, Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.8.5 Medicinova, Inc. Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.9.5 Merck & Co., Inc. Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Details
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG Idiopathic Pulmonary Fibrosis Treatment Introduction
11.10.4 Novartis AG Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.10.5 Novartis AG Recent Development
11.11 Prometic Life Sciences Inc.
11.11.1 Prometic Life Sciences Inc. Company Details
11.11.2 Prometic Life Sciences Inc. Business Overview
11.11.3 Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.11.4 Prometic Life Sciences Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.11.5 Prometic Life Sciences Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details